Loading patent…
AssigneeTargovax Asa
InventorsLukasz KURYK, Jon Amund ERIKSEN, Robert BURNS, Anne-Sophie MØLLER
Estimating the term…
The present invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing B7 family of immune-regulatory ligands and ADA in a cell and increasing anti-tumor effect and induction of specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing transgenes in a cell and increasing anti-tumor effect and generation of specific immune response in a subject.
An oncolytic adenoviral vector comprising an adenovirus serotype 5 (Ad5) nucleic acid backbone, a 24 base pair (bp) deletion (D24) in Rb binding constant region 2 of E1, a nucleic acid sequence encoding a member of the B7 family of costimulatory ligands, and a nucleic acid sequence encoding ADA in the E3 region.
(canceled)
Dependencies are inferred from the claim text.